<DOC>
	<DOCNO>NCT00958191</DOCNO>
	<brief_summary>The primary objective study demonstrate linear wear rate Trident速 X3 polyethylene insert superior polyethylene control group wear rate 5 year postoperative . This measurement evaluate compare digitize image serial radiograph obtain follow-up period 5-years .</brief_summary>
	<brief_title>Trident速 X3 Polyethylene Insert Study</brief_title>
	<detailed_description>The study prospective , multi-center , historical-controlled clinical evaluation Trident速 X3 Polyethylene insert . The device commercially available United States study conduct . The study device , Stryker Orthopaedics Trident速 X3 polyethylene insert , use replacement bear surface acetabulum relieve pain , instability , restriction motion due degenerative bone disease , include osteoarthritis , rheumatoid arthritis , trauma , failure device . The control device , Stryker Orthopaedics N2VAC polyethylene insert , also use replacement bear surface acetabulum relieve pain , instability , restriction motion due degenerative bone disease , include osteoarthritis , rheumatoid arthritis , trauma , failure device .</detailed_description>
	<criteria>1 . The patient sign IRBapproved , study specific Patient Informed Consent Form . 2 . The patient candidate primary total hip replacement cementless acetabular femoral component . 3 . The patient primary diagnosis NonInflammatory Degenerative Joint Disease ( NIDJD ) . Patient must diagnosis osteoarthritis ( OA ) , traumatic arthritis ( TA ) , avascular necrosis ( AVN ) , slip capital epiphysis , pelvic fracture , femoral fracture , fail fracture fixation , diastrophic variant . 4 . The patient male nonpregnant female patient age 21 75 . 5 . The patient willing able comply postoperative schedule clinical radiographic evaluation rehabilitation . 1 . The patient active infection affect hip joint . 2 . The patient require revision surgery previously implant total hip arthroplasty hip fusion affect joint . 3 . The patient BMI &gt; 45 . 4 . The patient neuromuscular neurosensory deficiency , limit ability evaluate safety efficacy device . 5 . The patient diagnose systemic disease ( i.e . Paget 's disease , renal osteodystrophy ) . 6 . The patient immunologically suppress receive chronic steroid excess 5mg per day . 7 . The patient recent history substance dependency may result deviation evaluation schedule . 8 . The patient prisoner .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>